The AFFINITY Study: Combination Treatment in PsA Dr. Antoni Chan reports on abstract OP0186 in London at EULAR 2026 https://t.co/LYQ1tshppm https://t.co/62Cm8b5Y1c

A Disease Seeking Its Identity: Peripheral SpA, PsA, and the SPARTACUS Evidence For years, pSpA has been managed with a cautious, stepwise approach: start with NSAIDs, escalate to conventional synthetic DMARDs, and only reach for biologics when everything else fails. The https://t.co/wXqU9ypD6t

EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases The 2026 EULAR vaccination recommendations, presented by Victoria Furer, were developed by a multinational 25-member task force that include rheumatologists, an https://t.co/AFnsmEYj41

Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/IFSHOM8g7w

Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs https://t.co/fNxEm31MAI

"When you make the choice to avoid becoming the most experienced person in a room (whatever room you’re in), you’re making a bet about the future. " - Seth Godin https://t.co/oWtDNWeoND https://t.co/2dpiFRGaxZ

From Cytokine Endotypes to Clinical Reality in Still’s Disease Recent EULAR 2026 data highlight a paradigm shift in Still’s disease from syndromic management to biologically informed precision therapy. https://t.co/fBtkDLPJNE https://t.co/y8NBW6VHHa

Genicular artery embolization (GAE) in knee OA? Multiple open label studies & metanalyses suggest a clear pain benefit; BUT 3 sham-controlled RCTs have not demonstrated a statistically significant benefit over placebo. GAE is not addressed by ACR or EULAR guidelines. https://t.co/amIN6kzY74

From BiTE to TriTE: Progress of T-cell Engagers in RMDs At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/jjXrf9tcaA

How many CAR-T’s do we need to test drive? There were 93 abstracts with CAR-T in title at #EULAR2026! Additionally, there was an excellent review (WIN) by Dr. Hector Chinoy. We know lots but have more questions. https://t.co/dGpfffaubX https://t.co/3MS1ZjQExj

Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/7HUqGGBeJ8